Dr. Enrique Alvarez
Claim this profileCU Anschutz Med Campus
Studies Multiple Sclerosis
Studies Systemic Sclerosis
6 reported clinical trials
15 drugs studied
Affiliated Hospitals
Clinical Trials Enrique Alvarez is currently running
Ozanimod
for Multiple Sclerosis
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
Recruiting3 awards Phase 44 criteria
BIIB091
for Relapsing Multiple Sclerosis
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part study. In Part 1, one set of participants will take either BIIB091 or diroximel fumarate (DRF). In Part 2, a different set of participants will take either a combination of BIIB091 and DRF or DRF alone. The goal of the study is to learn more about the safety of BIIB091 and to compare the effects of the study drug when taken alone or together with DRF. The main question researchers are trying to answer are: * How many participants have new or worsening medical problems (adverse events) after taking BIIB091 or DRF? * How many new areas of inflammation occur in the brain after treatment with BIIB091 and DRF? Researchers will use magnetic resonance imaging (MRI) scans to compare images of the brain before and after treatment. They will also explore the effect of BIIB091 and DRF on the heart using electrocardiograms (ECGs). The study will be done as follows: * After screening, participants who joined Part 1 will be randomly assigned to receive either a high or low dose of BIIB091, or the standard dose of DRF. * The results of Part 1 will be used to choose the best dose of BIIB091 to use in Part 2. * Participants who join Part 2 will be randomly assigned to receive either a standard dose of DRF, a combo of BIIB091 and the standard dose of DRF, or a combo of BIIB91 with a low dose of DRF. * Neither the researchers nor the participants will know which drug or dose the participants will receive in either part of the study. * The treatment period will last 48 weeks in each part of the study. Participants will take the drugs by mouth 2 times a day. * Each part will also have a follow-up safety period that lasts up to 2 weeks. * In total, participants in each part will have 20 study visits, or more if they have a relapse. The total study duration for participants will be up to 54 weeks.
Recruiting0 awards Phase 2
More about Enrique Alvarez
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Enrique Alvarez has experience with
- Ozanimod
- ATA188
- Early Highly Effective Therapies Group
- Escalation Therapies Group
- BIIB091
- DRF
Breakdown of trials Enrique Alvarez has run
Multiple Sclerosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Enrique Alvarez specialize in?
Enrique Alvarez focuses on Multiple Sclerosis and Systemic Sclerosis. In particular, much of their work with Multiple Sclerosis has involved treating patients, or patients who are undergoing treatment.
Is Enrique Alvarez currently recruiting for clinical trials?
Yes, Enrique Alvarez is currently recruiting for 3 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Enrique Alvarez has studied deeply?
Yes, Enrique Alvarez has studied treatments such as Ozanimod, ATA188, Early Highly Effective Therapies Group.
What is the best way to schedule an appointment with Enrique Alvarez?
Apply for one of the trials that Enrique Alvarez is conducting.
What is the office address of Enrique Alvarez?
The office of Enrique Alvarez is located at: CU Anschutz Med Campus, Aurora, Colorado 80045 United States. This is the address for their practice at the CU Anschutz Med Campus.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.